Gyre Therapeutics (GYRE) Preferred Stock Liabilities (2012 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Preferred Stock Liabilities of $64.5 million for Q4 2023, up 93.72% year-over-year from $33.3 million in Q4 2022, and up 93.72% quarter-over-quarter from $33.3 million in Q2 2023.
Gyre Therapeutics (GYRE) Preferred Stock Liabilities (2012 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Preferred Stock Liabilities for 5 consecutive years, with $64.5 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Preferred Stock Liabilities rose 93.72% year-over-year to $64.5 million; the TTM figure through Dec 2023 stood at $64.5 million (up 93.72% YoY), while the FY2023 annual figure was $64.5 million, up 93.72% from the prior year.
- Preferred Stock Liabilities rose to $64.5 million in Q4 2023 per GYRE's latest filing, from $33.3 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $64.5 million in Q4 2023 and bottomed at $33.3 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 22.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.43 Mn |
| Mar 31, 2026 | 115.88 Mn |
| Dec 31, 2025 | 113.03 Mn |
| Jun 30, 2025 | 107.55 Mn |
| Mar 31, 2025 | 104.90 Mn |
| Dec 31, 2024 | 102.33 Mn |
| Dec 31, 2023 | 64.53 Mn |
| Jun 30, 2023 | 33.31 Mn |
| Mar 31, 2023 | 33.31 Mn |
| Dec 31, 2022 | 33.31 Mn |
| Dec 31, 2014 | 108.88 Mn |
| Dec 31, 2013 | 104.64 Mn |
| Dec 31, 2012 | 98.90 Mn |